For more information about the IPFnet trials, please use the links provided below. These links will open a new window to the www.clinicaltrials.gov website.
ACE-IPF -- Information as posted on ClinicalTrials.gov.
ACE-IPF is no longer enrolling.
The ACE-IPF study (AJRCCM, 2012 Jul 1;186(1):88-95) showed that warfarin is ineffective and potentially harmful as a therapy for patients with this disease.
PANTHER-IPF -- Information as posted on ClinicalTrials.gov.
PANTHER-IPF is no longer enrolling.
PANTHER-IPF recently stopped one of its three arms by the DSMB after review of the data showed that the three-drug regimen of prednisone + azathioprine + NAC led to a significant increase in mortality and serious adverse events. This is a major finding, as the three-drug regimen is widely-used and has often been considered the de facto standard of care for this disease. The NIH considered these results so important that they released a clinical alert and FAQ on October 21, 2011.
The two remaining arms of the study, NAC alone against placebo is also no longer enrolling. The results will be published in 2014.
STEP-IPF -- Information as posted on ClinicalTrials.gov.
STEP-IPF is no longer enrolling.
The STEP-IPF study (NEJM 2010; 363; 620-8) showed that sildenafil has significant benefit in gas exchange, dyspnea, and quality of life in patients with advanced IPF.